P = 187	W &	U.S. Pater	PTO/SB/21 (01-03) Approved for use through 04/30/2003. OMB 0651-0031 nt and Trademark Office; U.S. DEPARTMENT OF COMMERCE			
18	Under the Paperwork Reduction Act of 1995, no pers	Application Number	on of information unless it displays a valid OMB control number.  10/672,950			
	TRANSMITTAL	Filing Date	September 26, 2003			
HAL	TRANSMITTAL FORM	First Named Inventor	Alanine et al.			
	(to be used for all correspondence after initial filing)	Art Unit	1625			
		Examiner Name	Dentz, Bernard I.			
	Total Number of Pages in This Submission	Attorney Docket Number	21004 US1			
	EN	CLOSURES (Check all tha	Approved for use through 04/30/2003. OMB 0651-0031 Trademark Office; U.S. DEPARTMENT OF COMMERCE Information unless it displays a valid OMB control number.  672,950 Idember 26, 2003 Inine et al.  5 Itz, Bernard I.  69  After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information  Status Letter Other Enclosure(s) (please Identify below):  OR AGENT  AGENT  AGENT  OR AGENT			
•	Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Response to Missing Parts/ Incomplete Application  Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addr Terminal Disclaimer  Request for Refund  CD, Number of CD(s)	to Group  Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter Other Enclosure(s) (please			
	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
	Firm or Individual Signature Date December 15, /2003	Mes				
	CERTIF	ICATE OF TRANSMISSION	N/MAILING			
t	·	d to the USPTO or deposited with the U	nited States Postal Service with sufficient postage as first class			
	Typed or printed Kimberly Prior	1 ()/2,				
	Signature Man how	la Att Des	Date 12/15/2003			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## PATENT APPLICATION



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors:

Alanine, et al.

Group: 1625

Serial No. 10/672,950, filed September 26, 2003

Examiner: Dentz, Bernard, I.

(Ref. No. 21004 US1)

CONJUGATED AROMATIC COMPOUNDS WITH A PYRIDINE SUBSTITUENT

## INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 December 15, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

None of the documents listed on Form PTO 1449 are being submitted because each document has been made of record in the parent application, Serial No. 10/277,002, filed October 21, 2002, which is pending.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/672,950

Filed: September 26, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

Attorney for Applicant(s)

Kimberly J. Prior (Reg. No. 41,483) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-6208

Telefax: (973) 235-2363

Substitute for form 1449A/PTO	Complete if Known		
INFORMATION DISCLOSURE	Application Number	10/672,950	
STATEMENT BY APPLICANT	Filing Date	September 26, 2003	
	First Name Inventor	Alanine, et al.	
(Use several sheets if necessary)	Group Art Unit	1625	
	Examiner Name	Dentz, Bernard, I.	
4 1 -6 1	Attaman Daalast Namban	01004 7701	

4					Ditailinio: 1 taile	L Circu, i	Jermana, I.	_
Sheet	1	of 1 Attorney Docket Number 21004		US1				
	*			U.S. PAT	ENT DOCUMENTS			
Examiner Initials'	Cite No.'	U.S Number	S. Patent Docum	ment Kind Code <sup>2</sup> (if known)	Name of Patentee or App Cited Document		Date of Publication Cited document MM-DD-YY	nt
	A1	5,962	,472		Bourson et al.		10/05/1999	
	A2	6,265	,426		Alanine et al.		07/24/2001	
	<b>A3</b>	6,310	,213		Alanine et al.		10/30/2001	
	A4	5,869	,676		ChuanSheng Niu et a	ાી.	02/09/1999	
	A5	5,648	,369		Pankaja K. Kadaba		07/15/1997	
			FO	REIGN P	ATENT DOCUMENTS			
Examiner Initials'	Cite No.'	Foreign Office <sup>3</sup>	Patent Docum	Kind Code <sup>5</sup>	Name of Patentee or Applicant of Cited Docur	1	Date of Publication of Cited Document	T <sup>6</sup>

## NON PATENT LITERATURE DOCUMENTS

F.Hoffmann-La Roche AG

MM-DD-YYYY

04/04/2001

Code<sup>5</sup>

EP 1088818

**B1** 

(if known)

Examiner Initials'	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	C1	Yasushi Honma et al., J. Med. Chem., Vol. 27, pp. 125-128 (1984)	
	<b>C2</b>	Roger Adams et al., JACS, Vol. 71, pp. 1186-1195 (1949)	
	C3	M. Adamczyk and D. Watt, J. Org. Chem., Vol. 49, pp. 4226-4237 (1984)	
	C4	Chenard & Menniti, Curr. Pharma. Des., Vol. 9, pp. 381-404 (1999)	
	C5	Kaminski J.J., et al., Journal of Medicinal Chemistry, Vol. 32, No. 8, pgs. 1686-1700 (1989)	
	<b>C6</b>	Chuansheng Niu, et al., Tetrahedron, Vol. 54, pgs. 6311-6318 (1998)	
	C7	Jun Li, et al., Current Medicinal Chemistry, Vol. 8, No. 2, pgs. 121-133 (2001)	
	C8	Takamura Keiichi, et al., Chemical Abstract XP002231553 & Yakugaku Zasshi, 91(8), pgs. 787-94 (1971)	
	<b>C9</b>	Padmanabhan, S., et al., Bioorganic & Medicinal Chemistry Letters, Vol. 11, pgs. 501-504 (2001)	
Examiner Signature		Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

Texaminate in reference considered, whether of not shadow an accommendation to applicant.

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation or abstract is attached.